Clinical Trials for Chronic Migraine
Chronic migraine is defined as having 15 or more headache days per month, with at least 8 of those meeting migraine criteria. It is disabling, affecting work, relationships, and quality of life in profound ways. Treatment has evolved significantly with the development of CGRP (calcitonin gene-related peptide) inhibitors, but insurance prior authorization and step therapy requirements create real barriers to accessing these newer preventive options.
Clinical trials are studying additional CGRP-pathway treatments, non-CGRP approaches, neuromodulation, and strategies for people whose chronic migraine has not responded to current options.
The American Migraine Foundation estimates that chronic migraine affects approximately 4 million Americans, with the condition having a significant impact on daily function.
What Types of Trials Are Available?
CGRP receptor antagonist trials (gepants) study oral preventive and acute treatments in the CGRP pathway. Rimegepant (Nurtec) and atogepant (Qulipta) are approved; newer agents and extended-use studies are in trials. Anti-CGRP monoclonal antibody trials build on erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality), studying longer dosing intervals, combination approaches, and use in people who have not responded to approved agents. Non-CGRP mechanism trials are studying treatments for chronic migraine that work through different pathways, which may help people who have not responded to CGRP inhibitors. Neuromodulation trials study non-drug approaches including transcranial magnetic stimulation (TMS) and electrical nerve stimulation devices. Migraine with comorbidities trials look at treating chronic migraine in people who also have anxiety, depression, or other common comorbid conditions.Search ClinicalTrials.gov for currently recruiting trials.
Am I Eligible?
Common eligibility factors for chronic migraine trials include:
- Confirmed chronic migraine diagnosis (15+ headache days/month for 3+ months, with 8+ meeting migraine criteria)
- Headache diary or documentation of migraine frequency
- History of prior preventive treatment attempts (most trials require documentation of 2-4 failed preventive therapies)
- No current medication overuse headache (some trials exclude this; others enroll it separately)
- No significant cardiovascular conditions for certain CGRP agents
Your neurologist or headache specialist is the right guide for evaluating your eligibility. Talk to your doctor before making any decisions about your treatment.
What If My Insurance Denied My Medication?
CGRP inhibitors for chronic migraine -- including erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and the gepant medications -- are commonly denied because insurers require documentation of failed trials of older, less well-tolerated preventives like topiramate, amitriptyline, or beta-blockers. This step therapy requirement can mean months of being on medications your doctor may not have chosen.
If your neurologist or headache specialist has recommended a CGRP inhibitor and your insurer has denied it, you can appeal -- and a strong appeal includes documentation of why older medications are inappropriate for your specific situation.
Clinical trials studying CGRP-pathway or alternative mechanism treatments may offer access while your appeal proceeds.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Are clinical trials for chronic migraine free?
In most cases, yes. Trial sponsors (pharmaceutical companies, universities, or the NIH) cover the cost of the experimental treatment. You may still have costs for routine care — like doctor visits or standard tests — depending on your insurance. Always ask the trial coordinator what costs you might be responsible for before enrolling.
How do I find chronic migraine trials near me?
The best place to start is ClinicalTrials.gov, the official registry of all trials in the US. Search by condition name and filter by your location. Your specialist can also help identify trials at academic medical centers in your region.
Can I join a trial after being denied Aimovig or Emgality?
Yes, and in many cases a denial can actually make you a stronger candidate — trials often enroll patients who have not responded to or cannot access standard treatments. Talk to your doctor about whether your denial history makes you eligible for open trials studying Aimovig or Emgality or similar medications.